SAN FRANCISCO--(BUSINESS WIRE)--Deal Labs, Inc., an online financing platform with targeted capital-raising solicitation technology, announced the closing of a $3.9 million Series A round for Consano Medical. In addition, Deal Labs announced today that Nueon Inc. has selected it to assist in raising capital.
Using a sophisticated stack of marketing automation, CRM and database technologies, Deal Labs identifies investors who are well suited for particular investments based on their industry expertise, professional experience, interests, prior investments, geographic location and other pertinent factors. Deal Labs then markets to these targeted investors, who can make an informed decision about the investment and have a significant understanding of the opportunity and risks associated with the investment. The benefit to the issuers is an efficient and direct method of raising capital from individual and institutional investors.
For Consano Medical, a medical device company spun out of the medical device incubator TheraNova and focused on the development of an intelligent monitoring device for detecting and managing sepsis in patients in intensive care units, Deal Labs’ innovative approach delivered investors who are ideally suited to the mission of the early-stage company.
“Deal Labs was critical to the success of our oversubscribed Series A,” stated Dan Burnett, M.D., CEO of Consano Medical. “Not only was this the fastest fundraise of my career, Deal Labs identified true value-added investors, many of whom we expect to be early adopters of our technology. They are very selective, but if you are raising capital for a high quality deal, then I would certainly recommend working with Deal Labs.”
“The successful closure of Series A funding for Consano Medical demonstrates that Deal Labs has created an alternative method of raising capital,” said Craig Harding, Deal Labs CEO. “The Deal Labs process worked beautifully. A group of clinical physicians, hospital administrators, and medical device development consultants organized by Ehrenberg Chesler Capital Partners San Antonio led the round, and well understood the IP owned by Consano, the preclinical data, and the medical need for new products to detect and treat sepsis.”
Nueon Inc. is currently raising capital through Deal Labs and Gordian Investments, LLC, which is Deal Labs’ affiliated broker-dealer. Nueon has developed the optical technology to measure red blood cell membrane chemistry and provide feedback about the three to four month history of blood pressure control and the resulting harmful effects of hypertension. Nueon’s technology helps provide actionable data to the physician at the point of care. Bob Messerschmidt, Founder and CEO of Nueon Inc., said “Deal Labs is not just building awareness of Nueon as an investment, but also the Nueon device as a radically improved method for detecting, managing and treating high blood pressure. Deal Labs can provide information about Nueon to medical specialists who understand the underlying science and the clinical need for the Nueon product, and who can make an informed decision about investing in Nueon.”
About Deal Labs
Deal Labs raises capital for private companies, public companies, and pooled investment funds and partnerships including real estate. Deal Labs selectively targets the type of retail and institutional investors who are believed to be best suited for a particular investment, thereby substantially improving and expediting the capital raising process. Rather than simply post information about offerings, Deal Labs uses a stack of technology to actively seek out and develop potential investors for selected companies and investment funds. For more information please visit www.deallabs.com
Please note that client testimonials may not be representative of the experience of other clients or their investors, and are no guarantee of future performance or success of an offering or an investment.
Securities offered through Gordian Investments, LLC. Member: FINRA, SIPC.